Saturday 31 October 2026 Export WST’s income statement to Excel — free account

West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

412.62 4.05 −0.97%

Follow WST

Alert me

Market cap: $29.3B
P/E: 52.5×
Fwd P/E: 48.1×
Dividend yield: 0.28%
F-score: 8/9
Altman Z: 13.89
Beneish M: −2.79
Dividend safety: 100/100

Overview Business Profile Earnings & Analysis Segments Filings

West Pharmaceutical Services, Inc. (WST) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Proprietary Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
West Vantage	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and Eliminations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Intersegment Eliminations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Unallocated Items	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

West Pharmaceutical Services, Inc. (WST) revenue by segment, product and region

Stockrow Weekly